FDA Grants Syros Pharmaceuticals Orphan Drug Designation For Treatment Of Pancreatic Cancer – FDA
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=898122
Adamis Achieves Enrolment Target In Mid-Stage Covid-19 Study, Awaits Data Safety Monitoring Board Review Later This Month
Adamis Pharmaceuticals (NASDAQ: ADMP) announced that it has reached the initial planned enrollment target in the ongoing U.S. Phase 2/3 clinical trial investigating Tempol as a treatment for COVID-19.
Cardiff Oncology Announces Plans For A Randomized Trial, Durability Of Responses In Ongoing Phase 1b/2 Trial In Metastatic Colorectal Cancer And Additional Business Updates
Next trial in RAS-mutated mCRC (ONSEMBLE) is a randomized Phase 2 trial to demonstrate onvansertib's contribution to SoC and position for a possible accelerated approval opportunity; topline data expected in 2H
Adamis Provides An Enrollment Update On The Phase 2/3 Study Of Tempol In COVID-19 Positive High-Risk Subjects
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19 has reached the
Agenus Begins Mid-Stage Global Studies On Colorectal And Skin Cancer Candidate
Agenus (NASDAQ: AGEN) has initiated Phase 2 ACTIVATE trials of botensilimab to advance globally in metastatic patients who have progressed on available therapies.
This global Phase 2 program include clinical trials of ACTIVATE-Colorectal and ACTIVATE-Melanoma studies.
BioLineRx Seeks FDA Nod For Stem Cell Mobilization Candidate
BioLineRx (NASDAQ: BLRX) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate Motixafortide in stem cell mobilization (SCM) for autologous bone marrow transplantation for multiple myeloma patients.
Analyst Outlines Doubts On This NASH-Focused Stock, Builds Neutral Case
HC Wainwright initiated Terns Pharmaceutical Inc (NASDAQ:TERN) with a Neutral rating and a price target of $6.00. The biopharmaceutical company has a…
This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says
HC Wainwright initiated coverage on Rain Therapeutics Inc (NASDAQ:RAIN), with a price target of $10 with a Buy rating. With an upside…
Deciphera Earns Price Target Bump With Encouraging ESMO Presentation
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) announced positive initial data from the single agent dose escalation portion of the Phase 1 study of…